Science
Novartis Pluvicto Shows Significant rPFS Benefit in Metastatic Hormone-Sensitive Prostate Cancer
The results, from an interim analysis of the trial, indicate that Pluvicto, when combined with standard-of-care hormone therapy, offers a clinically meaningful benefit over hormone therapy alone.
Subscriber access
Full story for subscribers
Sign in with your subscribed Google account to read the full article.
Checking your access…